First patients receive One-Time gene therapy for rare blood disorder
NCT ID NCT04105166
Summary
This early-stage study tested the safety of a one-time gene therapy for adults and children with pyruvate kinase deficiency, a rare genetic blood disorder. Doctors collected patients' own blood stem cells, corrected the faulty gene in a lab, and then infused the cells back. The main goal was to see if this process was safe, while also checking if it could reduce the need for blood transfusions and improve anemia.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PYRUVATE KINASE DEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Infantil Universitario Niño Jesús
Madrid, 28009, Spain
-
Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain
-
Stanford University
Stanford, California, 94304, United States
Conditions
Explore the condition pages connected to this study.